PGx7610: Genetic Evaluation of Hepatotoxicity in Pazopanib Studies (201761)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/16369
• EU PAS number:
  EUPAS7361
• Study ID:
  16369
• Official title and acronym:
  PGx7610: Genetic Evaluation of Hepatotoxicity in Pazopanib Studies (201761)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study status:
  Finalised

Research institution and networks

Institutions

GlaxoSmithKline (GSK)

Study timelines

Date when funding contract was signed

Planned: 27/06/2014

Actual: 27/06/2014

Study start date

Planned: 01/08/2014

Actual: 01/08/2014

Date of final study report

Planned: 31/12/2014

Actual: 17/02/2015

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

GlaxoSmithKline

Study protocol

Initial protocol

gsk-201761-reporting-and-analysis-plan-redact

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)